Report of a European concensus workshop to develop recommendations for the optimal use of 90Y-ibritumomab tiuxetan (Zevalin®) in lymphoma

Annals of Oncology

Volumn 16, Issue 5, 2005, Pages 786-792

  Hagenbeek, A ^a   Lewington, V ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

90Y ibritumomab tiuxetan; Guidelines; Haematologist; Lymphoma; Oncologist

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; IBRITUMOMAB TIUXETAN; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; STEROID; MONOCLONAL ANTIBODY; YTTRIUM;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ARTICLE; ASTHENIA; BLEEDING; CANCER RELAPSE; CANCER RISK; CHILL; CLINICAL TRIAL; CONSENSUS; DOSE CALCULATION; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG INFORMATION; DRUG LABELING; DRUG SAFETY; DRUG USE; ERYTHROCYTE TRANSFUSION; EUROPE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HUMAN; INFECTION; MALE; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; CANCER STAGING; COMPARATIVE STUDY; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; METHODOLOGY; MORTALITY; PATHOLOGY; PATIENT SELECTION; PRACTICE GUIDELINE; RADIOIMMUNOTHERAPY; SENSITIVITY AND SPECIFICITY; SURVIVAL;

ANTIBODIES, MONOCLONAL; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; NEOPLASM STAGING; PATIENT SELECTION; PRACTICE GUIDELINES; RADIOIMMUNOTHERAPY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; YTTRIUM RADIOISOTOPES;

EID: 20044387394     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi148     Document Type: Article

References (25)

1. Harris NL, Jaffe ES, Stein H et al. Lymphoma classification proposal: clarification. Blood 1995; 85: 857-860.
2. Reiser M, Diehl V. Current treatment of follicular non-Hodgkin's lymphoma. Eur J Cancer 2002; 38: 1167-1172.
3. Grillo-López AJ. Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev Anticancer Ther 2002; 2: 485-493.
4. European Medicines Agency. http://www.emea.eu.int/humandocs/PDFs/EPAR/zevalin/535103en4.pdf (28 June 2004, date last accessed).
5. Wiseman GA, Gordon LI, Multani PS et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99: 4336-4342.
6. Wiseman GA, Leigh B, Witzig T et al. Radiation exposure is very low to the family members of patients treated with yttrium-90 Zevalin™ anti-CD20 monoclonal antibody therapy for lymphoma. Eur J Nucl Med 2001; 28: 1198 (Abstr).
7. Wiseman GA, Leigh BR, Dunn WL et al. Additional radiation absorbed dose estimates for Zevalin™ radioimmunotherapy. Cancer Biother Radiopharm 2003; 18: 253-258.
8. Witzig TE, White CA, Gordon LI et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003; 21: 1263-1270.
9. Kantarjian HM, Keating MJ. Therapy-related leukemia and myelodysplastic syndrome. Semin Oncol 1987; 14: 435-443.
10. Kyle RA, Greipp, PR, Gertz MA et al. Waldenstrom's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 2000; 108: 737-742.
11. Pedersen-Bjergaard J, Ersboll J, Sorensen HM et al. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas: Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med 1985; 103: 195-200.
12. Kaminski MS, Bennett M, Tuck M et al. Lack of treatment-related MDS/AML in patients with follicular lymphoma after frontline therapy with tositumomab and iodine 131 tositumomab. Proc Am Soc Clin Oncol 2003; 22: 575 (Abstr).
13. Wiseman GA, White CA, Stabin M et al. Phase I/II90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 2000; 27: 766-777.
14. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 2003; 44: 465-467.
15. Wiseman L, Gordon B, Leigh T et al. Safety and efficacy of the Zevalin radioimmunotherapy regimen are not diminished by extending the time interval between rituximab infusion and Zevalin injection. Blood 2000; 96: 251B (Abstr).
16. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of Yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453-2463.
17. Gordon LI, Witzig TE, Murray JL et al. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with relapsed or refractory low grade, follicular or transformed B-cell NHL: final results of a randomized controlled trial. Proc Am Soc Clin Oncol 2003; 22: 576 (Abstr).
18. Witzig TE, Flinn IW, Gordon LI et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262-3269.
19. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-1253.
20. Ansell SM, Ristow KM, Habermann TM et al. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3885-3890.
21. 90Y ibritumomab (Zevalin) in aggressive non-Hodgkin's lymphoma: analysis of response and toxicity. Proc Am Soc Clin Oncol 2002; 21: 266a (Abstr).
22. 90Y-ibritumomab tiuxetan (Zevalin) radioimmunotherapy does not preclude effective delivery of subsequent therapy for lymphoma. Proc Am Soc Clin Oncol 2002; 21: 267a (Abstr).
23. Nadamanee A, Molina A, Forman SJ et al. A phase I/II trial of high-dose radioimmunotherapy (RIT) with Zevalin in combination with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous stem cell transplant (ASCT) in patients with poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL). Blood 2002; 100: 182a (Abstr).
24. Winter JN, Inwards D, Erwin W et al. Zevalin dose-escalation followed by high-dose BEAM and autologous peripheral blood progenitor cell (PBPC) transplant in non-Hodgkin's lymphoma: Early outcome results. Blood 2002; 100: 411a (Abstr).
25. 90Y-ibritumomab tiuxetan (Zevaling®). Blood 2003; 102: 4956a (Abstr).